Connect with us

Technology

Cryoport Reports Second Quarter 2026 Financial Results

Published

on

Second quarter revenue grew 8% year-over-year to $49.0 millionLife Sciences Services revenue increased 15% year-over-yearBioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026

NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Jerrell Shelton, CEO of Cryoport, commented, “Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological Solutions’ industry-leading cryogenic systems and the successful introduction of new and innovative products.

“Total revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million. The Life Science Services portion of our revenue from supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis continued to ramp. Total revenue for the quarter from supporting CGT clinical trials increased 12% year-over-year to $13.4 million as our customers’ clinical pipelines advanced and further matured. We supported a record 779 clinical trials globally as of June 30, 2026, reflecting the strength of our industry-leading position as the CGT market continues to advance.

“Our second quarter results also reflect meaningful progress on our “pathway to profitability.” Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives we have executed over the past several years. We are pleased with this accomplishment as we continue to optimize our global operations, leverage our expanding infrastructure, and benefit from the operating leverage that we anticipate will take effect as we increasingly scale and put our investments to work.

“Overall, we delivered a strong second quarter, generating growth across key revenue streams, improving profitability, and achieving an important milestone with positive adjusted EBITDA for the quarter. With our accomplishments to date, we believe that we are well positioned to further expand margins, enhance operating efficiency, and deliver sustainable, profitable long-term growth for our shareholders. We remain focused on executing our strategy, driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity,” concluded Mr. Shelton.

The following table presents Q2 2026 revenue compared with Q2 2025:

Cryoport, Inc. and Subsidiaries

Revenue 

Three Months Ended
June 30,
(unaudited)

Six Months Ended
June 30,
(unaudited)

(in thousands)

2026

2025

% Change

2026

2025

% Change

Life Sciences Services

$       27,969

$     24,369

15 %

$     54,867

$     47,234

16 %

BioLogistics Solutions

22,359

19,874

13 %

44,027

38,404

15 %

BioStorage/BioServices 

5,610

4,495

25 %

10,840

8,830

23 %

Life Sciences Products

$       21,002

$     21,085

0 %

$     41,902

$     39,260

7 %

Total Revenue

$       48,971

$     45,454

8 %

$     96,769

$     86,494

12 %

BioLogistics Solutions revenue increased 13% year-over-year in Q2 2026, driven by increasing customer activity, continued commercial product development, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of June 30, 2026, the number of commercial cell and gene therapies we support increased to 22 and our total clinical trial count that we support rose to 779 clinical trials worldwide, a net increase of 51 clinical trials over June 30, 2025, with 94 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

Clinical Trials

June 30,

2024

2025

2026

Phase 1

286

304

316

Phase 2

322

342

369

Phase 3

76

82

94

Total

684

728

779

Cryoport Supported Clinical Trials by Region

Clinical Trials

June 30,

2024

2025

2026

Americas

525

556

579

EMEA

114

124

145

APAC

45

48

55

Total

684

728

779

In Q2 2026, four of our customers filed Biologics License Applications (BLA) / Marketing Authorization Applications (MAA). During the Q2 2026, Cryoport’s customer, Orca Bio, received U.S. Food and Drug Administration (FDA) approval for TREGZI™ as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in the treatment of adults with hematological malignancies. Additionally, during Q2 2026, Vertex Pharmaceuticals received supplemental approval from the FDA to expand the label of CASGEVY® for the treatment of patients aged two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved gene therapy indicated for children as young as two years for both SCD and TDT. For the balance of 2026, we anticipate another 11 possible BLA/MAA applications, five possible additional new therapy approvals, and one possible additional approval for label/geographic expansion from our customer base.

Operational milestones

Cryoport Systems’ IntegriCell® cryopreservation services were selected by Verismo Therapeutics, a clinical-stage CAR T-cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).Advanced toward the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France, expected in Q4 2026.Continued progress toward the launch of our state-of-the-art Global Supply Chain Center in Santa Ana, California, expected in Q4 2026.Shipped first HE freezers “made in China for China” from our Chengdu, China manufacturing facility.

Financial Highlights

On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue

Total revenue for Q2 2026 was $49.0 million, compared to $45.5 million for Q2 2025, a year-over-year increase of 8%, or $3.5 million. Life Sciences Services revenue for Q2 2026 (representing 57% of our total revenue) was $28.0 million, compared to $24.4 million for Q2 2025, up 15% year-over-year, including BioStorage/BioServices revenue of $5.6 million, up 25% year-over-year. Life Sciences Products revenue for Q2 2026 (representing 43% of our total revenue) was $21.0 million, compared to $21.1 million for Q2 2025.Total revenue for H1 2026 was $96.8 million, compared to $86.5 million for H1 2025. Life Sciences Services revenue for H1 2026 was $54.9 million, compared to $47.2 million for H1 2025, including BioStorage/BioServices revenue of $10.8 million, compared to $8.8 million for H1 2025. Life Sciences Products revenue for H1 2026 was $41.9 million, compared to $39.3 million for H1 2025.

Gross Margin

Total gross margin was 46.6% for Q2 2026, compared to 47.0% for Q2 2025. Gross margin for Life Sciences Services was 49.9% for Q2 2026, compared to 48.9% for Q2 2025. Gross margin for Life Sciences Products was 42.2% for Q2 2026, compared to 44.9% for Q2 2025.Total gross margin was 46.2% for H1 2026, compared to 46.3% for H1 2025. Gross margin for Life Sciences Services was 49.4% for H1 2026, compared to 48.4% for H1 2025. Gross margin for Life Sciences Products was 42.1% for H1 2026, compared to 43.7% for H1 2025.

Operating Costs and Expenses

Operating costs and expenses were $32.9 million for Q2 2026, compared to $31.0 million for Q2 2025. Operating costs and expenses were $64.4 million for H1 2026, compared to $56.9 million for H1 2025.

Loss from Continuing Operations

Loss from continuing operations was $8.3 million for Q2 2026, compared to a loss of $12.0 million for Q2 2025. Loss from continuing operations was $17.7 million for H1 2026, compared to a loss of $18.8 million for H1 2025.

Net Income (Loss) – including Discontinued Operations

Net loss was $8.3 million for Q2 2026, compared to net income of $108.9 million for Q2 2025. Net loss for H1 2026 was $18.8 million, compared to net income of $96.9 million for H1 2025. Net income for Q2 2025 and H1 2025 was primarily driven by the sale of our CRYOPDP specialty courier business during Q2 2025, which contributed $120.9 million and $115.6 million, net of taxes, respectively, to income from discontinued operations.Net loss attributable to common stockholders for Q2 2026 was $10.3 million, or $0.20 per share. Net loss attributable to common stockholders for H1 2026 was $22.8 million, or $0.45 per share. This compares to net income attributable to common stockholders of $106.9 million, or $2.13 per share, and $92.9 million, or $1.85 per share, for Q2 2025 and H1 2025, respectively.

Adjusted EBITDA from Continuing Operations

Adjusted EBITDA from continuing operations was $0.4 million for Q2 2026, compared to a negative $0.9 million for Q2 2025. Adjusted EBITDA from continuing operations for H1 2026 was a negative $0.2 million, compared to a negative $3.7 million for H1 2025.

Cash, Cash equivalents, and Short-Term Investments

Cryoport held $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional Information

Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which is expected to be filed with the Securities and Exchange Commission (“SEC”) on August 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled “Cryoport Second Quarter 2026 in Review,” providing a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Thursday, August 6, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on August 6, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Thursday, August 6, 2026

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport Call” or Conference ID: 1142151

Live webcast:

‘Investor Relations’ section at www.cryoportinc.com or click here.

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company’s website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until August 13, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1142151#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are “Enabling the Future of Medicine™.” 

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company’s industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company’s outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company’s plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company’s clients. Forward-looking statements also include those related to the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s anticipation that it will benefit from its operating leverage, the Company’s belief that it is well positioned to further expand margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company’s expectation that upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company’s business could be affected by other factors discussed in the Company’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three Months Ended
June 30,
(unaudited)

Six Months Ended
June 30,
(unaudited)

(in thousands, except share and per share data)

2026

2025

2026

2025

Revenue

Life Sciences Services revenue

$                  27,969

$                 24,369

$                  54,867

$                 47,234

Life Sciences Products revenue

21,002

21,085

41,902

39,260

Total revenue

48,971

45,454

96,769

86,494

Cost of revenue:

Cost of services revenue

14,008

12,449

27,755

24,369

Cost of products revenue

12,139

11,628

24,277

22,107

Total cost of revenue

26,147

24,077

52,032

46,476

Gross margin

22,824

21,377

44,737

40,018

Operating costs and expenses:

Selling, general and administrative

28,011

26,908

55,631

48,809

Engineering and development

4,852

4,118

8,759

8,052

Total operating costs and expenses:

32,863

31,026

64,390

56,861

Loss from operations

(10,039)

(9,649)

(19,653)

(16,843)

Other income (expense):

Investment income

3,132

1,466

6,222

3,039

Interest expense

(518)

(618)

(950)

(1,201)

Other expense, net

(325)

(2,939)

(2,693)

(3,239)

Loss before provision for income taxes

(7,750)

(11,740)

(17,074)

(18,244)

Provision for income taxes

(505)

(274)

(613)

(508)

Loss from continuing operations

$                  (8,255)

$                (12,014)

$                (17,687)

$                (18,752)

Income (loss) from discontinued operations, net

120,883

(1,112)

115,640

Net income (loss)

$                  (8,255)

$               108,869

$                (18,799)

$                 96,888

Paid-in-kind dividend on Series C convertible preferred stock

(2,000)

(2,000)

(4,000)

(4,000)

Net income (loss) attributable to common stockholders

$                (10,255)

$               106,869

$                (22,799)

$                 92,888

Net income (loss) per share attributable to common stockholders – basic and diluted

$                    (0.20)

$                     2.13

$                    (0.45)

$                     1.85

Weighted average common shares issued and outstanding – basic and diluted

50,442,796

50,257,112

50,173,730

50,102,918

Gross margin – Total [%]

46.6 %

47.0 %

46.2 %

46.3 %

Gross margin – Services [%]

49.9 %

48.9 %

49.4 %

48.4 %

Gross margin – Products [%]

42.2 %

44.9 %

42.1 %

43.7 %

 

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

June 30,

December 31,

2026

2025

(in thousands)

(unaudited)

Current assets

Cash and cash equivalents

$                    269,267

$                    250,494

Short-term investments

127,426

160,714

Accounts receivable, net

36,454

33,359

Inventories

21,506

23,188

Prepaid expenses and other current assets

5,550

8,419

Total current assets

460,203

476,174

Property and equipment, net

94,516

85,448

Operating lease right-of-use assets

40,323

39,720

Intangible assets, net

135,992

138,082

Goodwill

22,068

22,400

Deposits

2,038

2,092

Deferred tax assets

1,064

1,073

 Total assets 

$                    756,204

$                    764,989

Current liabilities

Accounts payable and other accrued expenses

$                      16,247

$                      15,283

Accrued compensation and related expenses

12,186

12,980

Deferred revenue

1,720

943

Current portion of operating lease liabilities

3,937

4,133

Current portion of finance lease liabilities

448

422

Current portion of convertible senior notes, net

185,687

185,094

Current portion of notes payable

159

163

Current portion of contingent consideration

652

Total current liabilities

221,036

219,018

Notes payable, net

985

1,087

Operating lease liabilities, net

40,076

39,078

Finance lease liabilities, net

726

741

Deferred tax liabilities

1,850

1,354

Other long-term liabilities

832

444

Contingent consideration

629

Total liabilities

265,505

262,351

Total stockholders’ equity

490,699

502,638

Total liabilities and stockholders’ equity

$                    756,204

$                    764,989

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport’s ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport’s comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport’s GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport’s ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport’s underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport’s underlying business.

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)

Three Months Ended
June 30,

Six Months Ended
June 30,

2026

2025

2026

2025

(in thousands)

GAAP loss from continuing operations

$          (8,255)

$          (12,014)

$         (17,687)

$         (18,752)

Non-GAAP adjustments to loss:

Depreciation and amortization expense

6,589

6,249

12,991

12,383

Acquisition and integration costs

30

31

Cost reduction initiatives

140

266

140

482

Investment income

(3,132)

(1,466)

(6,222)

(3,039)

Unrealized (gain) loss on investments

(212)

1,082

1,893

1,275

Foreign currency loss

651

2,002

1,105

2,247

Interest expense, net

518

618

950

1,201

Stock-based compensation expense

2,402

2,045

4,797

5,109

Change in fair value of contingent consideration

27

42

(5,178)

Income taxes

505

274

613

508

Other adjustments

1,142

1,142

Adjusted EBITDA from continuing operations

$               375

$               (914)

$               (236)

$           (3,733)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-second-quarter-2026-financial-results-302845362.html

SOURCE Cryoport, Inc.

Continue Reading

Technology

Poll finds surging demand for AI-based video encoding

Published

on

By

HANGZHOU, China, Sept. 21, 2026 /PRNewswire/ — Hikvision has developed Guanlan Encoding, a technology that uses AI to identify more and less information-rich areas in video images and encodes every frame accordingly.

To gauge the potential impact of the new technology, asmag.com and Hikvision have teamed up for a survey of asmag readers, entitled “AI encoding technology for video security,” and asked them about their experience with the “storage challenge” and where they see potential in their projects for AI-based encoding.

Storage pressure is real and growing

When asked “How significant a challenge is video storage cost or capacity in your business or projects?” a large number of respondents—38.2%—identified storage pressure as a “major challenge.” It was the second-most given answer among all respondents, trailing closely behind 43.2% who said storage is a “moderate” challenge. When asked “Has the storage challenge changed compared to 12 months ago?” the largest share of respondents—once again 43.2%—said it has “increased moderately.” 

Guanlan Encoding—Hikvision’s solution to a growing pain point

Guanlan Encoding is built on the H.265 standard and integrates Hikvision’s Guanlan Large-Scale AI Model into continuous encoding workflows. Rather than compressing every part of a frame equally—the approach traditional codecs take—Guanlan Encoding identifies which parts of a scene matter most, such as people, vehicles and other moving objects, and allocates more detail to them. Static or low-motion background footage, by contrast, is compressed far more aggressively.

According to Hikvision, this combination of different compression rates in the same frame helps reduce storage needs by 30% to 50% on average without sacrificing details that matter for investigations and monitoring.

Guanlan is already gaining ground

Even though it was introduced so recently, over half of survey respondents expressed familiarity with Guanlan Encoding: 43.3% said they are “familiar with it” despite not yet having hands-on experience, while 8.3% said they are already using the technology.

Overall, the survey showed the severity of the storage challenge, but also that Hikvision is well positioned to offer a significant fix to the pain point. Guanlan Encoding plays a key role as it uses AI not to produce more data, but to reduce the burden of more data on storage infrastructure.

Find more reporting about the “AI encoding technology for video security” on the dedicated landing page on asmag.com, or download the full results of the survey.

View original content to download multimedia:https://www.prnewswire.com/news-releases/poll-finds-surging-demand-for-ai-based-video-encoding-302885423.html

SOURCE Hikvision Digital Technology

Continue Reading

Technology

Noah Holdings Hosts 2026 Global Investor Summit “The Year of Realization: A New Chapter in Global Allocation”

Published

on

By

Serving Global Chinese Families With a Global Investment Network, Licensed Teams and AI Capabilities

HONG KONG, Sept. 21, 2026 /PRNewswire/ — Noah Holdings Limited (“Noah” or the “Company”) (NYSE: NOAH; HKEX: 6686), a wealth management institution serving global Chinese families, together with its global asset allocation platform Olive Asset Management (“Olive”), successfully held its 2026 Global Investor Summit, themed “The Year of Realization: A New Chapter in Global Allocation,” in Hong Kong. Addressing the industry transformation driven by AI and the long-term wealth needs of global Chinese families, Noah discussed how it is combining the global investment network and professional expertise it has developed over the years with AI capabilities to build a wealth management system that clients can use and rely on over the long term.

Investment professionals from Global Infrastructure Partners (GIP, a part of BlackRock), Macquarie Asset Management, Bridgepoint, HarbourVest Partners and Sumitomo Mitsui Trust Asset Management attended the summit and participated in discussions. Noah’s global network of investment managers is an important foundation of its investment capabilities. Through its ongoing investments in funds globally, Noah and Olive continue to build relationships with managers and accumulate underlying research data, drawing on these resources to understand industry shifts, validate investment judgments and support clients’ long-term asset allocation.

Understanding the Responsibility of Wealth Management, Starting From Clients’ Long-Term Interests

Noah Holdings believes that the productivity shift brought by AI is changing how wealth is created and is placing new demands on families’ long-term planning. Wealth management needs to understand the long-term forces behind changes in technology, capital and family needs, while also factoring in family governance and succession. The responsibility of professional institutions is to help clients understand these changes and make judgments based on their own needs, building trust through long-term engagement.

Noah Holdings Chairwoman Norah Wang said: “Care is what expertise is for – that has always been Noah’s foundation. Our job is not to predict events, but to identify forces. Real care means using professional judgment to help clients see clearly which fluctuations they can bear, and which risks they must avoid.”

Noah Holdings CEO Zander Yin said at the summit that every technological revolution rewrites the world order and redraws the map of resources. The productivity shift now being driven by AI is no exception – it is likewise changing the path for corporate growth and investor participation.

Yin said: “The industrial revolutions of the past freed human hands; this AI revolution is further extending the human brain and human intelligence. Noah’s long-accumulated insight into GPs lets us keep observing how leading investment institutions make their choices. With AI, we are connecting this accumulated knowledge into clearer research threads – this ‘map’ is the trajectory of choices made by the world’s leading institutions. Following this map to identify companies worth deeper research is the approach we take.”

These judgments ultimately need to be embedded in a system clients can use. Noah’s three platforms operate in coordination: ARK Wealth Management handles account services and investment execution, covering the global banking system, trading channels, mutual funds and structured products; Olive Asset Management is responsible for long-term asset allocation, covering private equity, venture capital, real estate and global infrastructure; and Glory Family Heritage focuses on family protection and intergenerational planning, providing global family succession and lifestyle services. The three platforms work together within a unified framework to translate clients’ long-term needs into concrete investment, allocation and succession arrangements.

Noah Olive’s “Institutional Intelligence”: Making Judgment Evidence-Based and Experience Cumulative

Olive Asset Management Global CEO Peng Jing said at the summit that Olive is continuing to build its “institutional intelligence,” turning the research, decisions and experience accumulated through long-term investment practice into shared organizational methods and standards, so that professional judgment can accumulate over time, be tested, and improve through practice.

Observing the choices made by top-tier institutions is the starting point for research, not the conclusion. A global network of managers provides breadth of research, but institutional prestige and the number of investments alone cannot substitute for judgment. The team tracks how many genuinely independent sources of information support a given judgment, rather than simply counting how many firms have co-invested. At the execution level, Olive evaluates company quality and purchase price separately; at the research level, screening models need to be tested using only the information available at each historical point in time, with the methodology then refined based on actual outcomes. Project data, the basis for decisions, and the lessons drawn from both successes and mistakes are thereby retained within the organization over time. In this process, AI helps expand information coverage, detect anomalies and maintain ongoing tracking, while the professional team remains responsible for industry judgment, risk assessment and final decisions.

The summit also included a series of breakout sessions on topics such as cutting-edge technology in Silicon Valley, positioning in global private markets, opportunities in public markets, and family succession planning, with professionals from Noah and partner institutions taking part in the discussions.

Noah will continue to connect global investment resources, professional research and client service, working through its platforms to support the long-term investment and wealth succession needs of global Chinese families.

About Noah Holdings Limited

Noah Holdings Limited (NYSE: NOAH; HKEX: 6686) is a Singapore-headquartered wealth management institution focused on serving global Chinese high-net-worth families. Founded in 2005, Noah listed on the New York Stock Exchange in 2010 and completed a dual primary listing on the Hong Kong Stock Exchange in 2022. The Company’s business spans nine countries and regions, with account and trading centers in Singapore, Hong Kong, China, the United States, and Shanghai, China.

Disclaimer:

This press release is for reference only and does not constitute investment advice, an offer, or a solicitation of an offer to invest. Investing involves risk; the prices of securities and funds can rise as well as fall, and past performance is not indicative of future performance. The forward-looking statements contained in this release are subject to a variety of risks and uncertainties, and actual results may differ materially from these statements.

View original content:https://www.prnewswire.com/news-releases/noah-holdings-hosts-2026-global-investor-summit-the-year-of-realization-a-new-chapter-in-global-allocation-302885425.html

SOURCE Noah Holdings Limited

Continue Reading

Technology

When Music Reads Emotion: THEi Launches Centre for Music Therapy Research to Deepen Guangdong-Hong Kong Integration and Leverage AI to Fill the Healthcare Talent Gap

Published

on

By

Download high-res photo here: https://bit.ly/4rcZWOx 

HONG KONG, Sept. 22, 2026 /PRNewswire/ — The fast pace of modern life and an aging population drive demand for mental health and non-pharmacological holistic wellness. In alignment with the health development priorities of the national 15th Five-Year Plan and the Healthy China Initiative, the Technological and Higher Education Institute of Hong Kong (THEi) held the launch ceremony for its Centre for Music Therapy Research (CMTR) at the Sky Concert Hall in Shenzhen on 16 September. The launch aims to address the demand for innovative healthcare talent while fostering Guangdong-Hong Kong integration.

The event gathered prominent leaders across government, business, higher education, and technology sectors, including Mr Paul CHONG Kin-lit, BBS, MH, Vice Chairman, THEi’s Board of Governors; Professor Alan LAU Kin-tak, President of THEi; Ms LIU Ying,

Adjunct Associate Professor, Department of Digital Innovation and Technology, THEi and

Director of Centre for Music Therapy Research, THEi; Mr YANG Pengda, Education Entrepreneur and Deputy Director of Centre for Music Therapy Research, THEi;  Mr WAN Kun, Deputy Director-General, Development and Reform Bureau of Futian District, Shenzhen Municipality; Ms MA Hui, Director of Tchaikovsky Conservatory (China) International Exchange Centre; Dr CAI Yuejun, Key Laboratory of AI-Enabled Music Therapy, Shanghai Conservatory of Music; Dr PANG Yan, Associate Research Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS); Doctoral Supervisor, University of Chinese Academy of Sciences (UCAS).

The event featured strategic partnership signing ceremonies and a cross-industry networking reception, alongside an immersive “Emotional Healing Show” concert performed by celebrated musicians, including winners of ‘Golden Bell Awards’ and ‘Wenhua Award’, as well as former members of the renowned Twelve Girls Band. A key highlight was the live instrumental and choral performance of the iconic pop song Beneath the Lion Rock, which resonated with the Centre’s positioning of “Hong Kong’s International Connectivity”—marking a major milestone of advancing interdisciplinary mind-body wellness in the GBA.

Empowering Big Health with Applied Sciences: Nurturing “Work-Ready” Professionals in the GBA

Mr Paul CHONG Kin-lit, BBS, MH, Vice Chairman, THEi’s Board of Governors, delivered opening remarks, stating: “As an applied discipline bridging art, science, and medicine, music therapy plays a pivotal role in tackling mental stress, broader wellness demands, and specialised healthcare needs. Guided by our education philosophy of ‘applied science and immediate application,’ THEi drives industry-academia-research integration. By extending the reach of our Centre to Shenzhen, we leverage the GBA’s innovative ecosystem and expanding demand to pair global music therapy standards with cutting-edge technology—building a premier hub for scientific research, practical application, and community service.”

Professor Alan LAU Kin-tak, President of THEi, emphasised in his keynote that higher education must stay attuned to modern trends and national developments: “Music is undergoing a redefinition where sound, emotion, and AI intersect. As a pioneer in applied science and work-ready education, THEi sees growing demand in the GBA for expertise in non-pharmacological therapies, mental wellness, and the silver economy. By launching the Centre in Shenzhen, we fuse academic research with regional innovation. Through short-term and professional training programmes, we aim to fast-track market-ready, multidisciplinary talent equipped with technological, clinical, and commercial expertise to directly address key social needs.

Top Academic Talent Joins Forces

The newly launched Music Therapy Research Centre is directed by Ms LIU Ying, Visiting Associate Professor in the Department of Digital Innovation and Technology at THEi. A distinguished expert in Chinese traditional music, Ms LIU leads the Centre’s core content strategy, backed by international innovation expertise from Dr PANG Yan, Associate Research Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS); Doctoral Supervisor, University of Chinese Academy of Sciences (UCAS) and his team.

As the champion of the Guzheng category at the 9th Chinese Music ‘Golden Bell Awards’, and the exclusive recipient of the gold, silver, and bronze awards in this category. Ms LIU noted that the Centre maximises synergy between Hong Kong and Shenzhen by pairing “Hong Kong’s global perspective with Shenzhen’s development speed” to construct a regional cross-disciplinary hub. Guided by the vision of “medical treatment in hospitals, healing in daily life,” the Centre uses Five-Tone theory and AI-based EEG technologies to deliver non-clinical wellness solutions. She stressed that with a clear focus on problem-solving over sheer size, the Centre will advance practical training programs, therapeutic products, and industry benchmarks through the integration of arts, science, and commercialisation.

Mr YANG Pengda, Education Entrepreneur and Deputy Director of Centre for Music Therapy Research, THEi, underscored his belief that “investing in education is a high-value commitment, not a cost,” – a vision driving his multi-year support for THEi’s research centres. Praising THEi’s work-ready degree’s programmes – which features a 100% internship placement and over 95% graduate employment, he noted that the Institute’s programmes are tailored to industry needs. He emphasised that the new Centre is grounded in societal demand, tackling issues like sleep disorders affecting 300 million individuals and elder care for 320 million seniors—effectively leveraging technology and humanity to improve the quality of lives.

The Centre signed strategic MoUs with Key Laboratory of AI-Enabled Music Therapy, Shanghai Conservatory of Music and Tchaikovsky Conservatory (China) International Exchange Centre The partnerships will foster deep collaboration across music arts research, professional talent training, and international exchange, laying a solid artistic foundation for the Centre’s ongoing development.

Moving ahead, the Centre will focus its efforts on four core strategic pillars: advancing AI-assisted music therapy research to improve personalised non-pharmacological treatments; exploring traditional Chinese music to unlock its therapeutic emotional benefits; delivering arts-based healing to support seniors and individuals with special needs; and integrating digital music with immersive technology to drive music therapy beyond traditional stages into a smart, holistic era of care.

Following the official launch of the Centre and its upcoming professional training programmes, THEi is set to reinforce its leadership in regional applied science education—accelerating sustainable innovation to support high-quality development across the GBA and nationwide.

About the Bachelor of Arts (Honours) in Music Technology

The programme places a strong emphasis on cross-cultural exchange, covering three major professional domains: game music design, contemporary music composition, and film scoring. By integrating artificial intelligence and augmented reality/virtual reality (AR/VR) technologies into practical learning, the programme equips students with professional mastery in audio engineering and sound design, enhancing their ability to combine artistic creativity with technological innovation.

About Technological and Higher Education Institute of Hong Kong (THEi) 

Founded in 2012, the Technological and Higher Education Institute of Hong Kong (THEi) is a member institute of the Vocational Training Council (VTC). THEi offers over 20 professional “Applied Science-Oriented” undergraduate and postgraduate degree programmes across seven academic areas: Product and Fashion Designs, Sports and International Events Management, Digital Construction and Building Services, Horticulture, Arboriculture and Landscape Management, Chinese Medicine and Food Science, Hotel Management and Culinary Arts and Technology, and Digital Technology and Innovative Business. The programmes integrate theoretical knowledge with practical applications, and cover industries with growth potential in Hong Kong and the Asia-Pacific region, ensuring that students can apply what they learn effectively.

THEi’s undergraduate and postgraduate degree programmes are accredited by the Hong Kong Council for Accreditation of Academic and Vocational Qualifications. The curriculum emphasises the practical application of applied science, aligning with the latest developments in business and industry. The undergraduate degree programmes offer 100% work-integrated learning training to support students in building their career paths at an earlier stage.

THEi Chai Wan Campus was awarded the “Leadership in Sustainable Design and Performance Award – Institutional” of the Asia Pacific Leadership in Green Building Awards presented by the World Green Building Council (WorldGBC) in 2020.

Media Contact:

Ms Janice Lam 
Tel: (852) 3890 8227 / (852) 9718 0817
Email: janicelam@thei.edu.hk / media@thei.edu.hk

Ms  Rainbow Chiu 
Tel: (852) 3890 8520
Email: rainbowh@thei.edu.hk  / media@thei.edu.hk

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/when-music-reads-emotion-thei-launches-centre-for-music-therapy-research-to-deepen-guangdong-hong-kong-integration-and-leverage-ai-to-fill-the-healthcare-talent-gap-302885463.html

SOURCE Technological and Higher Education Institute of Hong Kong (THEi)

Continue Reading

Trending